Vedolizumab

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Vedolizumab

CAS No. : 943609-66-3

MCE 国际站：Vedolizumab

产品活性：Vedolizumab 是一种靶向 α4β7 整联蛋白 (integrin) 的人源化 IgG1 单克隆抗体，用于溃疡性结肠炎和克罗恩病的相关研究。

研究领域：Cytoskeleton

作用靶点：Integrin

In Vitro: Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC₅₀=0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC₅₀=0.02-0.06 μg/mL) and fibronectin (IC₅₀=0.02 μg/mL), but not vascular cell adhesion molecule 1.

In Vivo: Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups.

相关产品：Cilengitide  |  Cyclo(-RGDfK)  |  GLPG0187  |  Cucurbitacin B  |  E7820  |  MK-0429  |  CWHM-12  |  ATN-161 trifluoroacetate salt  |  Lifitegrast  |  Pyrintegrin  |  Arg-Gly-Asp-Ser  |  GPRP acetate  |  Tirofiban  |  Fibronectin  |  Carotegrast methyl  |  αvβ1 integrin-IN-1 TFA  |  iRGD peptide  |  Bexotegrast  |  A-205804  |  Eptifibatide  |  RGD peptide (GRGDNP) (TFA)  |  Natalizumab  |  Tetrac  |  Firategrast  |  Leukadherin-1  |  OSU-T315  |  Cyclo(RGDyK) trifluoroacetate  |  Etrolizumab

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds